(MENAFN- GlobeNewsWire - Nasdaq) The main market opportunities in the CRO industry for Q3 2025 include identifying emerging trends in clinical trial trends, dominant CROs and sponsors, popular therapeutic areas, and regional activity, enabling stakeholders to strategize and capitalize on geographical performance and therapeutic demands.

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "Q3 2025 CRO Activity and Intel Report" report has been added to ResearchAndMarkets's offering.
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q3 2025.
Report Scope

• The Q3 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.

Reasons to Buy

• What are the trends by region, therapy area, sites by CROs for the past quarter?
• Who was the most active CRO in the past quarter?
• Who were the most active sponsors by market cap in the past quarter?
• What was the most widely studied therapy area in the past quarter vs. the previous year's quarter?
• By region, who had the most clinical trials initiated in the past quarter?
• By region, what were the past quarter's CRO invitations and appointments?

Key Topics Covered:

Introduction

• Global
• CRO and sponsor activity in Q3 2025
• Most-used CROs
• Most active large- and mega-cap sponsors
• Most active mid-cap sponsors
• Most active small-cap sponsors

Clinical trials in oncology and CNS

• Therapeutic area breakdown of clinical trials initiated in Q3 2025 vs. Q3 2024
• Trials initiated in the 10 most active oncology indications in Q3 2025 vs. Q3 2024
• Trials initiated in the 10 most active CNS indications in Q3 2025 vs. Q3 2024
• Top 10 CROs by number of sites in Q3 2025

North America

• Clinical trial activity in North America in Q3 2025
• Most active North American regions in Q3 2025 vs. Q3 2024
• Phase breakdown of trials initiated in North America in Q3 2025 vs. Q3 2024
• Therapeutic area breakdown of clinical trials initiated in North America in Q3 2025 vs. Q3 2024
• Top 10 trial sites by trials initiated in North America in Q3 2025
• Insights: CRO invites for sponsors based in North America
• Insights: CRO appointments for sponsors based in North America

Europe

• Clinical trial activity in Europe in Q3 2025
• Most active European regions in Q3 2025 vs. Q3 2024
• Phase breakdown of trials initiated in Europe in Q3 2025 vs. Q3 2024
• Therapeutic area breakdown of clinical trials initiated in Europe in Q3 2025 vs. Q3 2024
• Top 10 trial sites by trials initiated in Europe in Q3 2025
• Insights: CRO invites for sponsors based in Europe

Rest of the world

• Clinical trial activity in ROW in Q3 2025
• Most active regions in ROW in Q3 2025 vs. Q3 2024
• Phase breakdown of trials initiated in ROW in Q3 2025 vs. Q3 2024
• Therapeutic area breakdown of clinical trials initiated in ROW in Q3 2025 vs. Q3 2024
• Top 10 trial sites by trials initiated in ROW in Q3 2025

Companies Featured

• ICON
• Astrazeneca
• Akesobio
• CSPPC Pharmaceutical
• ImmunityBio
• Boryung

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN25112025004107003653ID1110395266